Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.
Crewe HK, Barter ZE, Yeo KR, Rostami-Hodjegan A. Crewe HK, et al. Among authors: yeo kr. Biopharm Drug Dispos. 2011 Sep;32(6):303-18. doi: 10.1002/bdd.760. Epub 2011 Jul 4. Biopharm Drug Dispos. 2011. PMID: 21725985
Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.
Yeo KR, Yeo WW. Yeo KR, et al. Among authors: yeo ww. Br J Clin Pharmacol. 2001 May;51(5):461-70. doi: 10.1046/j.1365-2125.2001.01386.x. Br J Clin Pharmacol. 2001. PMID: 11422004 Free PMC article.
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A. Heydari A, et al. Among authors: yeo kr. Drug Metab Dispos. 2004 Nov;32(11):1213-7. doi: 10.1124/dmd.104.001180. Epub 2004 Aug 24. Drug Metab Dispos. 2004. PMID: 15328252
Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.
Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Yang J, et al. Among authors: yeo kr. Eur J Pharm Sci. 2005 Nov;26(3-4):334-40. doi: 10.1016/j.ejps.2005.07.005. Eur J Pharm Sci. 2005. PMID: 16137870
Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.
Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Yang J, et al. Among authors: yeo kr. Eur J Pharm Sci. 2007 Jul;31(3-4):232-41. doi: 10.1016/j.ejps.2007.04.005. Epub 2007 Apr 25. Eur J Pharm Sci. 2007. PMID: 17512176
Prediction of intestinal first-pass drug metabolism.
Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Yang J, et al. Among authors: yeo kr. Curr Drug Metab. 2007 Oct;8(7):676-84. doi: 10.2174/138920007782109733. Curr Drug Metab. 2007. PMID: 17979655 Review.
Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.
Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Yang J, et al. Among authors: yeo kr. Curr Drug Metab. 2008 Jun;9(5):384-94. doi: 10.2174/138920008784746382. Curr Drug Metab. 2008. PMID: 18537575 Review.
Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
Barter ZE, Perrett HF, Yeo KR, Allorge D, Lennard MS, Rostami-Hodjegan A. Barter ZE, et al. Among authors: yeo kr. Biopharm Drug Dispos. 2010 Nov;31(8-9):516-32. doi: 10.1002/bdd.732. Biopharm Drug Dispos. 2010. PMID: 21104927
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.
Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, Barter ZE. Cubitt HE, et al. Among authors: yeo kr. Xenobiotica. 2011 Aug;41(8):623-38. doi: 10.3109/00498254.2011.560294. Epub 2011 Mar 24. Xenobiotica. 2011. PMID: 21434772
Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.
Yeo KR, Kenny JR, Rostami-Hodjegan A. Yeo KR, et al. Eur J Clin Pharmacol. 2013 Jun;69(6):1311-20. doi: 10.1007/s00228-012-1467-3. Epub 2013 Jan 11. Eur J Clin Pharmacol. 2013. PMID: 23307233
22 results
Jump to page
Feedback